Publication: The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
1
Issued Date
2020-04-01
Resource Type
ISSN
14744457
14733099
14733099
Other identifier(s)
2-s2.0-85082182997
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet Infectious Diseases. Vol.20, No.4 (2020), e51-e60
Suggested Citation
Ramanan Laxminarayan, Thomas Van Boeckel, Isabel Frost, Samuel Kariuki, Ejaz Ahmed Khan, Direk Limmathurotsakul, D. G.Joakim Larsson, Gabriel Levy-Hara, Marc Mendelson, Kevin Outterson, Sharon J. Peacock, Yong Guan Zhu The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. The Lancet Infectious Diseases. Vol.20, No.4 (2020), e51-e60. doi:10.1016/S1473-3099(20)30003-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/54612
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
Other Contributor(s)
Kenya Medical Research Institute
Shifa International Hospital
University of Cambridge
ETH Zürich
Hospital General de Agudos Carlos G. Durand
Boston University
Göteborgs Universitet
Imperial College London
Mahidol University
Research Center for Eco-Environmental Sciences Chinese Academy of Sciences
Groote Schuur Hospital
Princeton University
Center for Disease Dynamics
Shifa International Hospital
University of Cambridge
ETH Zürich
Hospital General de Agudos Carlos G. Durand
Boston University
Göteborgs Universitet
Imperial College London
Mahidol University
Research Center for Eco-Environmental Sciences Chinese Academy of Sciences
Groote Schuur Hospital
Princeton University
Center for Disease Dynamics
Abstract
© 2020 Elsevier Ltd In 2013, a Lancet Infectious Diseases Commission described the state of antimicrobial resistance worldwide. Since then, greater awareness of the public health ramifications of antimicrobial resistance has led to national actions and global initiatives, including a resolution at the high-level meeting of the UN General Assembly in 2016. Progress in addressing this issue has ranged from a ban on irrational drug combinations in India to commitments to ban colistin as a growth promoter in animals, improve hospital infection control, and implement better antimicrobial stewardship. Funds have been mobilised, and regulatory barriers to new antibiotic development have been relaxed. These efforts have been episodic and uneven across countries, however. Sustained funding for antimicrobial resistance and globally harmonised targets to monitor progress are still urgently needed. Except for in a few leading countries, antimicrobial resistance has not captured the sustained focus of national leaders and country-level actors, including care providers.